

**Towards the Co-clinical Glioblastoma Treatment Paradigm - Radiomic Machine Learning Identifies Glioblastoma Gene Expression in Patients and Corresponding Xenograft Tumor Models**

Pascal O. Zinn MD PhD; Sanjay K. Singh PhD; Aikaterini Kotrotsou; Islam Hassan; Markus M. Luedi MD; Ginu Thomas; Nabil Elshafeey; Jennifer Mosley; Ahmed Elakkad; Tagwa Idris; Joy Gumin BS; Gregory N. Fuller MD, PhD; John F. de Groot; Veera Baladandayuthapani PhD; Erik P Sulman MD, PhD; Ashok Mahapatra Kumar; Raymond Sawaya MD; Frederick F.

**Introduction**

Radiomics is extraction of multi-dimensional imaging-features which when correlated with genomics is termed radiogenomics. The radio-genomic relationship has never been biologically validated. Towards creating a co-clinical glioblastoma treatment paradigm, we sought to establish causality between differential gene expression status and MRI-extracted radiomic-texture features in glioblastoma.

**Methods**

Radiogenomic predictions and validation were done using orthotopic xenograft models (N=40) and the Cancer Genome Atlas glioblastoma patient cohort with matched imaging (N=94). Tumor phenotypes were segmented and radiomic-features extracted using machine learning algorithms. Patients and animals were dichotomized based on Periostin (POSTN) expression levels. RNA and protein levels confirmed RNAi-mediated POSTN knockdown. Total RNAs of tumor cells isolated from mouse brains (knockdown and control) was used for microarray-based expression profiling. Radiomic-features were then utilized to predict POSTN expression status in patient and mouse, and inter-species.

**Results**

Our robust machine learning based analytical pipeline consists of segmentation, radiomic texture extraction, feature normalization and selection, and predictive-model generation. POSTN expression status was not associated with qualitative or volumetric MRI parameters. However, radiomic-features significantly predicted POSTN expression status in both patients (AUC 100%, sensitivity/specificity: 100%/100%) and animal model (AUC 95.24%, sensitivity/specificity: 100%/88.88%). Furthermore, texture-features in xenografts were significantly associated with humans with similar POSTN expression levels (AUC 74.36%, sensitivity/specificity: 74.42%/87.17%; p-value 0.0279).

**Conclusions**

We established a high degree of causality between radiomic texture-features and POSTN expression levels in a pre-clinical model with clinical validation. Our biologically validated machine learning based radiomic pipeline also showed potential application in human-mouse matched co-clinical trials and opens an avenue for the personalized co-clinical glioblastoma treatment paradigm.

**Learning Objectives**

MRI based machine learning unlocks untapped information from routine brain tumor imaging and allows for establishing co-clinical trial models and ultimately glioblastoma treatment paradigms to augment personalized medicine in cancer care.

[Default Poster]